Abnormal Toxicity Testing for Single-Use Medical Consumables: Standards, Methods, and Regulatory Com

Abnormal toxicity testing is a fundamental biological safety evaluation for single-use medical consumables such as syringes, infusion sets, catheters, and blood-contacting devices. By administering device extracts to mice and observing for adverse systemic reactions, this screening test detects unexpected toxic contaminants introduced by raw materials, manufacturing processes, sterilization, or packaging. This article explains the applicable standards, sample types, test methods, judgment criteria, and regulatory applications of abnormal toxicity testing for disposable medical consumables.

Technical Overview

Abnormal toxicity testing is a whole-animal safety screening procedure designed to verify that single-use medical consumables do not release harmful quantities of toxic substances under simulated clinical extraction conditions. The method is rooted in pharmacopoeial practice and is widely applied in the biological evaluation of disposable infusion, transfusion, and injection equipment, as well as during registration type testing of medical devices in regulated markets.

Unlike targeted chemical assays, the abnormal toxicity test functions as a broad, non-specific safety net. It integrates the combined biological impact of all leachable substances, including polymer additives, catalyst residues, processing aids, lubricants, sterilant residues such as ethylene oxide, and contaminants introduced during production or storage. A passing result demonstrates that the total burden of extractable toxicants, administered at doses representing exaggerated clinical exposure, does not produce acute systemic injury in the test animal.

The test is typically performed in accordance with the Chinese Pharmacopoeia general methods for abnormal toxicity, GB/T 14233.2 for infusion, transfusion, and injection equipment, and, for devices intended for international markets, the ISO 10993 series framework, in particular ISO 10993-11 for systemic toxicity and ISO 10993-12 for sample preparation. Comparable in vivo safety screens exist in United States Pharmacopeia general chapters covering biological reactivity testing.

Testing Samples

Abnormal toxicity testing applies to any sterile single-use consumable that contacts the body, body fluids, or pharmaceuticals destined for administration. Typical sample categories include the following.

Injection and Infusion Consumables

• Disposable sterile syringes, needles, and needle-free connectors
• Single-use infusion sets, blood transfusion sets, and intravenous administration sets
• Infusion filters, stopcocks, extension lines, and injection ports
• Prefilled syringe barrels, plungers, and elastomeric closures

Blood-Contact and Extracorporeal Consumables

• Vacuum blood collection tubes, sampling needles, and blood lancets
• Blood storage bags, apheresis kits, and leukocyte depletion filters
• Hemodialyzers, hemoperfusion cartridges, and extracorporeal blood lines
• Oxygenators, reservoirs, and cardiopulmonary bypass circuits

Body-Cavity and Tissue-Contact Consumables

• Urinary catheters, drainage tubes, and gastroenteral feeding tubes
• Endotracheal tubes, breathing circuits, and anesthesia masks
• Surgical gloves, drapes, wound dressings, and adhesive products
• Laparoscopic and minimally invasive single-use access instruments

Delivery and Packaging Components

• Inhalation and nasal delivery devices, spacers, and masks
• Primary packaging films, blister materials, and container closures for parenterals
• Single-use laboratory consumables intended for clinical sample handling

Testing Items

Testing programs for single-use consumables are structured around the intended route and duration of body contact. Core and complementary items include the following.

• Abnormal toxicity test, intravenous route: the classical pharmacopoeial screen in which a saline extract of the device is injected into mice to detect unacceptably toxic leachables.
• Abnormal toxicity test, intraperitoneal route: an alternative administration route used when intravenous injection is unsuitable for the extract or when the standard specifies it.
• Acute systemic toxicity test per ISO 10993-11: a structured evaluation using both polar and non-polar extracts, blank controls, and defined observation endpoints at multiple time points.
• Systemic injection safety test per USP biological reactivity methods: required for many devices and materials submitted to North American markets.
• Supporting biological items frequently tested in combination: hemolysis, pyrogen or bacterial endotoxin testing, intracutaneous irritation, and delayed-type sensitization.

Testing Methods

Sample Preparation and Extraction

Devices are cleaned of external contaminants, and a representative portion is extracted in a defined medium, most commonly 0.9 percent sodium chloride injection or water for injection. Extraction ratios follow the surface-area-to-volume conventions of ISO 10993-12, with proportionally scaled ratios for irregular geometries. Standard extraction conditions include 37 plus or minus 1 degree Celsius for 24 plus or minus 2 hours, or accelerated conditions of higher temperature for validated equivalences. A blank extraction control prepared without the test sample is processed in parallel to distinguish device-related effects from solvent or handling artifacts.

Test System and Animal Welfare

The test system consists of healthy mice, typically 17 to 20 grams in the pharmacopoeial method, with five animals per group for routine screening and larger groups for confirmatory testing. Animals are acclimatized, randomly assigned, and housed under controlled environmental conditions. All procedures are performed under institutional animal ethics approval with strict application of the principles of reduction, refinement, and replacement, and the test is designed to use the minimum number of animals needed for a valid conclusion.

Administration Routes

For the intravenous route, the extract is injected via the tail vein at the pharmacopoeial dose, commonly 0.5 milliliters per mouse, while ISO 10993-11 protocols may use doses up to 50 milliliters per kilogram of body weight as tolerated by the route and formulation. The intraperitoneal route is used when the extract cannot be given intravenously, such as for oil-based or particulate-containing media. Control animals receive the blank extract through the same route at the same dose.

Observation and Judgment Criteria

Animals are observed immediately after dosing and at defined intervals through the observation window, typically 48 hours for the pharmacopoeial abnormal toxicity test and up to 72 hours for ISO-based acute systemic toxicity. Recorded endpoints include mortality and overt signs of toxicity such as convulsions, prostration, respiratory distress, abnormal locomotion, and marked weight loss. The sample passes when all test animals survive and display no obvious toxic reactions compared with controls. If any animal dies or shows clear signs of toxicity, the test is repeated with a doubled group size; consistent findings in the retest constitute a failure requiring investigation. Test reports document extraction parameters, animal data, clinical observations, and a reasoned pass or fail conclusion.

Applications

Abnormal toxicity data supports multiple quality, regulatory, and commercial objectives across the product lifecycle.

• Registration and type testing: mandatory biological evidence in device registration dossiers for single-use consumables submitted to authorities such as the NMPA in China.
• Batch release and routine quality control: periodic or per-lot safety screening to confirm that production remains free of unexpected toxic contamination.
• Change validation: verification of material substitutions, supplier changes, process modifications, or sterilization cycle adjustments to demonstrate continued biological safety.
• International market access: biocompatibility packages for CE technical documentation and FDA submissions, where in vivo safety data complement chemical and toxicological risk assessments.
• Procurement and tender support: independent test reports demonstrating conformity for hospital tenders, distributor qualification, and export certification.
• Root cause investigation: diagnostic screening when raw material, cleaning agent, or packaging anomalies raise concerns about potential biological hazard.

FAQ

What is the difference between abnormal toxicity testing and acute systemic toxicity testing?

Abnormal toxicity testing is a pass or fail pharmacopoeial safety screen focused on detecting any unexpected gross toxic effect within a short observation period, historically serving as a release criterion for injectable products and device extracts. Acute systemic toxicity under ISO 10993-11 is a more structured biocompatibility study using multiple extraction media, control groups, defined time points, and graded comparison against controls. In practice, the two methods overlap substantially, and many registration portfolios include both to satisfy pharmacopoeial and device-specific requirements.

Which standards govern the test for single-use consumables?

Primary references include the Chinese Pharmacopoeia general method for abnormal toxicity, GB/T 14233.2 for biological test methods applicable to infusion, transfusion, and injection equipment, ISO 10993-11 for systemic toxicity, ISO 10993-12 for sample preparation, and the USP general chapters for biological reactivity. The applicable standard set depends on the target market and the product classification.

How many samples are required and how long does testing take?

Sample requirements depend on device geometry and the surface area needed to prepare the extract at the mandated ratio; laboratories usually request a defined number of sterile production units plus retention samples. The core timeline is short, since extraction takes about one day and the observation window lasts two to three days, so results are commonly available within one to two weeks including report preparation, subject to laboratory scheduling.

What should a manufacturer do if a sample fails the test?

A failure triggers a structured investigation covering raw material certificates, compounding additives, manufacturing hygiene, cleaning and sterilization residues, and packaging interactions. Targeted chemical analysis, such as gas chromatographic screening for volatile leachables or ethylene oxide residuals, is typically combined with a repeat abnormal toxicity test or a redesignated ISO 10993 evaluation to isolate the causative factor before resubmission.

Can chemical characterization replace abnormal toxicity testing?

Modern biocompatibility strategies increasingly favor extractables and leachables profiling combined with toxicological risk assessment, and some regulatory pathways accept this approach when the risk assessment is comprehensive. However, in markets where the abnormal toxicity test remains a pharmacopoeial or registration requirement for disposable consumables, the in vivo screen is still expected, and the two approaches are best viewed as complementary rather than interchangeable.